These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

758 related items for PubMed ID: 18565302

  • 1. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J.
    Ugeskr Laeger; 2008 Jun 09; 170(24):2152-6. PubMed ID: 18565302
    [Abstract] [Full Text] [Related]

  • 2. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM.
    Dan Med Bull; 2011 Dec 09; 58(12):B4360. PubMed ID: 22142578
    [Abstract] [Full Text] [Related]

  • 3. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB.
    Gut; 2007 Sep 09; 56(9):1181-3. PubMed ID: 17698862
    [Abstract] [Full Text] [Related]

  • 4. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.
    Bousvaros A.
    Expert Rev Clin Immunol; 2010 Jul 09; 6(4):659-66. PubMed ID: 20594138
    [Abstract] [Full Text] [Related]

  • 5. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.
    Dig Liver Dis; 2005 Jun 09; 37(6):407-17. PubMed ID: 15893279
    [Abstract] [Full Text] [Related]

  • 6. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Van Assche G, Vermeire S, Rutgeerts P.
    Curr Opin Gastroenterol; 2009 Jul 09; 25(4):323-8. PubMed ID: 19417645
    [Abstract] [Full Text] [Related]

  • 7. [Current medical treatment of inflammatory bowel disease].
    Bosques-Padilla F.
    Rev Gastroenterol Mex; 2007 Nov 09; 72 Suppl 2():92-101. PubMed ID: 18277494
    [No Abstract] [Full Text] [Related]

  • 8. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S.
    Am J Gastroenterol; 2011 Feb 09; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [Abstract] [Full Text] [Related]

  • 9. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
    Leung Y, Hanauer SB.
    Gastroenterol Clin Biol; 2009 Jun 09; 33 Suppl 3():S202-8. PubMed ID: 20117343
    [Abstract] [Full Text] [Related]

  • 10. [Immunosuppression in inflammatory bowel disease: When, how and how long?].
    Gross V.
    Dtsch Med Wochenschr; 2012 Sep 09; 137(37):1803-5. PubMed ID: 22956222
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul 09; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

  • 12. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM, Schmidt D, Karlén P.
    Lakartidningen; 2009 Jul 09; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract] [Full Text] [Related]

  • 13. [Inflammatory bowel diseases--new therapeutic options].
    Herrlinger K, Stange EF.
    Med Klin (Munich); 2008 Feb 15; 103(2):90-101; quiz 102-3. PubMed ID: 18270665
    [No Abstract] [Full Text] [Related]

  • 14. Update on idiopathic colitides.
    Strobel S, Abreu MT.
    Curr Opin Gastroenterol; 2013 Jan 15; 29(1):60-5. PubMed ID: 23207597
    [Abstract] [Full Text] [Related]

  • 15. [CED therapy with infliximab. Rapid and lasting remission - complete mucosal healing].
    Wedekind S.
    MMW Fortschr Med; 2011 Dec 01; 153(48):54-5. PubMed ID: 22299262
    [No Abstract] [Full Text] [Related]

  • 16. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B.
    Aliment Pharmacol Ther; 2009 Aug 01; 30(3):253-64. PubMed ID: 19438424
    [Abstract] [Full Text] [Related]

  • 17. [Drug treatment of chronic inflammatory bowel diseases: current status and prospects].
    Seibold F, Wagner AC, Göke B.
    Schweiz Med Wochenschr; 2000 Feb 19; 130(7):222-32. PubMed ID: 10719713
    [Abstract] [Full Text] [Related]

  • 18. [Therapy of chronic inflammatory bowel diseases].
    Beglinger C.
    Ther Umsch; 1997 Nov 19; 54(11):649-53. PubMed ID: 9454368
    [Abstract] [Full Text] [Related]

  • 19. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
    Bischoff A.
    MMW Fortschr Med; 2010 Jan 14; 152(1-2):20. PubMed ID: 20302159
    [No Abstract] [Full Text] [Related]

  • 20. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
    Orlando A, Armuzzi A, Papi C, Annese V, Ardizzone S, Biancone L, Bortoli A, Castiglione F, D'Incà R, Gionchetti P, Kohn A, Poggioli G, Rizzello F, Vecchi M, Cottone M, Italian Society of Gastroenterology, Italian Group for the study of Inflammatory Bowel Disease.
    Dig Liver Dis; 2011 Jan 14; 43(1):1-20. PubMed ID: 20843756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.